Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas J Conlon

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Human Gene Therapy|July 9, 2009
Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 yearArtur V Cideciyan, William W Hauswirth, Tomas S Aleman, et al.
Genetic Vaccines and Therapy|June 20, 2012
An acidic oligopeptide displayed on AAV2 improves axial muscle tropism after systemic deliveryNi-Chung Lee, Darin J Falk, Barry J Byrne, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2010
Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established diseaseCathryn S Mah, Darin J Falk, Sean A Germain, et al.
Human Gene Therapy|August 1, 2012
The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retinaShannon E Boye, John J Alexander, Sanford L Boye, et al.
Nature Communications|November 28, 2025
Gene therapy delivery of anti-Müllerian hormone in prepubertal female domestic cats induces long-term sterilizationPhilippe Godin, Nicholas Nagykery, Natalie Sicher, et al.
Human Gene Therapy. Clinical Development|May 23, 2013
Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosaThomas J Conlon, Wen-Tao Deng, Kirsten Erger, et al.
Human Gene Therapy. Clinical Development|October 4, 2018
Toxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 MiceChunjuan Song, Thomas J Conlon, Wen-Tao Deng, et al.
Human Gene Therapy|September 1, 2006
Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosisSamuel G Jacobson, Sanford L Boye, Tomas S Aleman, et al.
Human Molecular Genetics|April 27, 2011
Pompe disease gene therapyBarry J Byrne, Darin J Falk, Christina A Pacak, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 29, 2006
Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injectionSamuel G Jacobson, Gregory M Acland, Gustavo D Aguirre, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Human Gene Therapy|July 9, 2009
Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 yearArtur V Cideciyan, William W Hauswirth, Tomas S Aleman, et al.
Genetic Vaccines and Therapy|June 20, 2012
An acidic oligopeptide displayed on AAV2 improves axial muscle tropism after systemic deliveryNi-Chung Lee, Darin J Falk, Barry J Byrne, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2010
Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established diseaseCathryn S Mah, Darin J Falk, Sean A Germain, et al.
Human Gene Therapy|August 1, 2012
The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retinaShannon E Boye, John J Alexander, Sanford L Boye, et al.
Nature Communications|November 28, 2025
Gene therapy delivery of anti-Müllerian hormone in prepubertal female domestic cats induces long-term sterilizationPhilippe Godin, Nicholas Nagykery, Natalie Sicher, et al.
Human Gene Therapy. Clinical Development|May 23, 2013
Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosaThomas J Conlon, Wen-Tao Deng, Kirsten Erger, et al.
Human Gene Therapy. Clinical Development|October 4, 2018
Toxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 MiceChunjuan Song, Thomas J Conlon, Wen-Tao Deng, et al.
Human Gene Therapy|September 1, 2006
Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosisSamuel G Jacobson, Sanford L Boye, Tomas S Aleman, et al.
Human Molecular Genetics|April 27, 2011
Pompe disease gene therapyBarry J Byrne, Darin J Falk, Christina A Pacak, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 29, 2006
Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injectionSamuel G Jacobson, Gregory M Acland, Gustavo D Aguirre, et al.
Pageof 5